Annovis Bio Inc (ANVS) - News Archive

MALVERN, Pa., June 05, 2024 Annovis Bio Inc. (NYSE: ANVS) (Annovis or the Company), a pioneering late-stage clinical drug platform company, is set to host an investor webcast to provide an in-depth discussion on recent...

Novel Pharmacokinetic Insights Into Posiphen Across Species Uncovered by Annovis Revolutionary Analysis Published by Annovis in Respected Journal MALVERN, Pa., May 21, 2024 Annovis Bio, Inc. (NYSE: ANVS) (Annovis or the...

In an exciting development for Annovis Bio, the clinical-stage drug platform company has released a letter to stockholders from its esteemed Founder, President, and CEO, Maria Maccecchini. The letter showcased the posit...

Breakthrough Data Shows Promising Results for Annovis Bio s Buntanetap in Early Alzheimer s DiseaseMALVERN, Pa., April 29, 2024 - Annovis Bio, Inc. (NYSE: ANVS), a pioneer in developing novel therapies for neurodegenera...

In recent years, the scientific community has been eagerly investigating potential therapeutic interventions for neurodegenerative disorders, such as Alzheimer s disease (AD). Among the numerous candidates, Buntanetap h...

In a recent announcement, Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company specializing in novel therapies for neurodegenerative diseases, revealed the successful completion of data cleaning for it...

Annovis Bio, a clinical-stage drug platform company focused on developing innovative therapies for neurodegenerative diseases, has reported the completion of the last patient s final visit in the Phase II/III study of t...

Annovis Bio Delays Parkinson s Phase III Study Data Announcement for Improved Accuracy and ReliabilityMALVERN, Pa., Jan. 24, 2024 - Annovis Bio, Inc. (NYSE: ANVS), a renowned clinical-stage drug platform company special...

Annovis Bio, a groundbreaking clinical-stage drug platform company focused on combating neurodegenerative diseases, has recently achieved a significant milestone in the development of its lead compound, buntanetap. Acco...

Annovis Bio Announces Public Offering as Neurodegenerative Disease Therapies AdvanceBERWYN, Pa. - Annovis Bio, Inc. (NYSE: ANVS), a leading late-stage clinical drug platform company specializing in transformative therap...